Can celiac disease and other small-intestinal enteropathies cause secondary exocrine pancreatic insufficiency?

The link between small-intestinal enteropathies and secondary exocrine pancreatic insufficiency (EPI) is well-established. In conditions like celiac disease, the functional impairment of the pancreas occurs not because of damage to the organ itself, but because the intestinal signaling pathways required to trigger its activity are compromised.

Clinical and effectiveness evidence

Secondary EPI is a frequent finding in patients with active intestinal disease. Research indicates a significant prevalence of EPI among those with celiac disease, particularly in untreated cases.

• Prevalence: A 2024 meta-analysis found a pooled prevalence of EPI in 13.5% of patients with celiac disease, rising to 18.2% in those who were untreated.
• Biomarker findings: Clinical assessment frequently relies on fecal elastase-1 (FE-1). Levels below 200 μg/g are common in active celiac disease, indicating insufficient pancreatic enzyme output.
• Reversibility: Clinical evidence shows that secondary EPI is often reversible. Once the intestinal mucosa heals (for example, following a strict gluten-free diet), the signaling pathways typically restore, leading to normalized pancreatic function.

Mechanistic explanations

The pathophysiology of secondary EPI centers on the destruction of the intestinal endocrine environment.

• Hormonal signaling: The small intestine contains specialized enteroendocrine cells: I-cells (producing cholecystokinin/CCK) and S-cells (producing secretin). These hormones are the primary triggers for the pancreas to release digestive enzymes and bicarbonate.
• Mucosal atrophy: In enteropathies, villous atrophy and epithelial damage reduce the density and surface area of these hormone-producing cells. This loss impairs the gut's ability to sense luminal triggers like fats and acids, resulting in a failure to release CCK and secretin.
• Enzyme production: Without these hormonal signals, a structurally normal pancreas remains "dormant," failing to secrete adequate levels of enzymes, including elastase, into the intestinal tract.
• Dilutional effects: In cases of active malabsorption and diarrhea, increased luminal fluid may also dilute the concentration of fecal elastase, contributing to lower measured levels even if some secretion is present.

Bottom line

Celiac disease and other enteropathies cause secondary exocrine pancreatic insufficiency by destroying the mucosal cells responsible for secretin and CCK signaling. This lack of hormonal stimulation directly results in reduced pancreatic enzyme output and low fecal elastase levels, a process that is usually reversible with mucosal healing.